Efficacy and safety of using caspofungin, voriconazole, liposomal amphotericin B or their combination as therapy for invasive fungal disease in hematological malignancies

Invasive fungal disease (IFD) poses a significant threat to the lives of patients with hematological malignancies. However, it remains unclear whether monotherapy or combination antifungal treatment is more effective for these patients. To address this question, our study aimed to evaluate and compare the efficacy and safety of antifungal combination therapies versus monotherapies in the treatment of IFD in patients with hematological malignancies. This study compared the response rates to treatment, breakthrough IFD, IFD-associated deaths and overall mortality within 90 days, and adverse events in patients with hematological malignancies who were clinically diagnosed with IFD or suspected IFD and who had received caspofungin (CAS), voriconazole (VRC), or liposomal amphotericin B (L-AmB) or their combination. CAS, VRC, and L-AmB monotherapies were administered to 150, 148, and 50 patients, respectively; 65, 54, and 26 patients received CAS + VRC, CAS + L-AmB, and VRC + L-AmB combination therapies, respectively. The response rates did not differ significantly among the CAS, VRC, and CAS + VRC combination groups (P > 0.05), and this combination was not associated with significantly different outcomes in this cohort. The response rates were higher for CAS and VRC than for L-AmB monotherapy (P < 0.05). All adverse events were more common in patients receiving L-AmB monotherapy or combination therapy than in those receiving CAS monotherapy (P < 0.05). The overall adverse event rate was higher with L-AmB monotherapy than with VRC monotherapy (P < 0.05). In this cohort, patients who received CAS + VRC, CAS + L-AmB, or VRC + L-AmB were not associated with significantly different outcomes compared with those receiving CAS or VRC monotherapy; however, given the retrospective, single-centre design and the small subgroup sizes, these findings are exploratory and cannot establish equivalence or superiority between monotherapy and combination therapy. The use of L-AmB seems to be associated with a higher incidence of adverse reactions. • The response rates did not differ among the caspofungin, voriconazole, and their combination groups. • Caspofungin and voriconazole are associated with statistically higher response rates than liposomal amphotericin B. • Voriconazole is associated with more hepatotoxicity. • Liposomal amphotericin B is associated with more hypokalemia and nephrotoxicity.

Authors

Institutions

Publication Details

Journal
BMC Pharmacology and Toxicology
Published
2026-11-15
DOI
https://doi.org/10.1186/s40360-026-01285-y
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and safety of using caspofungin, voriconazole, liposomal amphotericin B or their combination as therapy for invasive fungal disease in hematological malignancies

Liuxin Feng, 张金铭, Jiao Xie, Yuanming Xing et al.
BMC Pharmacology and Toxicology
Antifungal resistance and susceptibility
article

Efficacy and safety of using caspofungin, voriconazole, liposomal amphotericin B or their combination as therapy for invasive fungal disease in hematological malignancies

Liuxin Feng, 张金铭, Jiao Xie, Yuanming Xing, Qianting Yang, Youjia Li, Na Wang, Yan Wang, Haitao Wang, Yan Cai
article en

Abstract

Invasive fungal disease (IFD) poses a significant threat to the lives of patients with hematological malignancies. However, it remains unclear whether monotherapy or combination antifungal treatment is more effective for these patients. To address this question, our study aimed to evaluate and compare the efficacy and safety of antifungal combination therapies versus monotherapies in the treatment of IFD in patients with hematological malignancies. This study compared the response rates to treatment, breakthrough IFD, IFD-associated deaths and overall mortality within 90 days, and adverse events in patients with hematological malignancies who were clinically diagnosed with IFD or suspected IFD and who had received caspofungin (CAS), voriconazole (VRC), or liposomal amphotericin B (L-AmB) or their combination. CAS, VRC, and L-AmB monotherapies were administered to 150, 148, and 50 patients, respectively; 65, 54, and 26 patients received CAS + VRC, CAS + L-AmB, and VRC + L-AmB combination therapies, respectively. The response rates did not differ significantly among the CAS, VRC, and CAS + VRC combination groups (P > 0.05), and this combination was not associated with significantly different outcomes in this cohort. The response rates were higher for CAS and VRC than for L-AmB monotherapy (P < 0.05). All adverse events were more common in patients receiving L-AmB monotherapy or combination therapy than in those receiving CAS monotherapy (P < 0.05). The overall adverse event rate was higher with L-AmB monotherapy than with VRC monotherapy (P < 0.05). In this cohort, patients who received CAS + VRC, CAS + L-AmB, or VRC + L-AmB were not associated with significantly different outcomes compared with those receiving CAS or VRC monotherapy; however, given the retrospective, single-centre design and the small subgroup sizes, these findings are exploratory and cannot establish equivalence or superiority between monotherapy and combination therapy. The use of L-AmB seems to be associated with a higher incidence of adverse reactions. • The response rates did not differ among the caspofungin, voriconazole, and their combination groups. • Caspofungin and voriconazole are associated with statistically higher response rates than liposomal amphotericin B. • Voriconazole is associated with more hepatotoxicity. • Liposomal amphotericin B is associated with more hypokalemia and nephrotoxicity.

BMC Pharmacology and Toxicology
First Affiliated Hospital of Xi'an Jiaotong University (CN), Second Affiliated Hospital of Xi'an Jiaotong University (CN), Xi'an Jiaotong University (CN)
Antifungal resistance and susceptibility
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon